Analyst Ratings For Legend Biotech
Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter:
Barclays Initiates Coverage On Legend Biotech with Overweight Rating, Announces Price Target of $53
Barclays analyst Gena Wang initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Overweight rating and announces Price Target of $53.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment
Key takeaways:
GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that
Legend Biotech’s Cilta-cel CAR-T cell therapy product was approved by the FDA on Monday, and could become a major cash cow for GenScript Biotech
By Molly Wen
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.
Morgan Stanley Upgrades Legend Biotech to Overweight, Announces $51 Price Target
Morgan Stanley analyst Matthew Harrison upgrades Legend Biotech (NASDAQ:LEGN) from Equal-Weight to Overweight and announces $51 price target.
Morgan Stanley Downgrades Legend Biotech to Equal-Weight
Morgan Stanley analyst Matthew Harrison downgrades Legend Biotech (NASDAQ:LEGN) from Overweight to Equal-Weight.
18 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce proteinuria in lgA nephropathy.